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disease (PD). We evaluated the independent impact of dyskine-
sia on QoL in patients with PD and evaluated whether com-
monly used QoL instruments are sensitive enough to measure
dyskinesia effects in clinical trials. METHODS: We analyzed
data from the German PD Competence Network comprising
generic (EuroQoL [EQ-5D]) and disease-speciﬁc (PD Question-
naire 39 [PDQ-39]) QoL instruments and clinical variables
including the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS).
We used 4 dyskinesia-speciﬁc UPDRS items (i.e., duration, dis-
ability, painfulness of dyskinesias and presence of early-morning
dystonia) to predict totals and subscores of EQ-5D and PDQ-
39, values of the visual analogue scale (VAS) and EQ-5D derived
utilities. We performed ordinal logistic regression to predict EQ-
5D subscales and multiple linear regression to predict all remain-
ing QoL outcomes. Potential confounders were speciﬁed a priori
by an expert panel and ﬁnal confounders were selected based on
statistical criteria (univariate Spearman’s rank correlation, mul-
tivariate forward selection, p < 0.05). RESULTS: A total of 68
models were investigated (4 dyskinesia ¥ 17 QoL variables), of
which 9 showed a statistically signiﬁcant association after con-
trolling for confounding. The most relevant confounder was
severity of disease. All 4 dyskinesia variables were associated
with at least 1 QoL variable. Dyskinesia duration was shown to
be the most robust predictor. Subscales of EQ-5D and PDQ-39
addressing pain/(bodily) discomfort were associated with all 4
dyskinesia variables. In addition, EQ-5D index was associated
with duration of dyskinesia. CONCLUSIONS: Dyskinesia has a
signiﬁcant impact on QoL measured by EQ-5D and PDQ-39 and
their subscales, even after controlling for confounding. EQ-5D
and PDQ-39 are useful instruments for clinical trials addressing
questions on the effect of potential anti-dyskinesia treatments on
QoL.
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OBJECTIVES: Utility data is often needed in health economic
modeling, but not always available in clinical studies in Parkin-
son’s disease (PD). Therefore, we have recently presented a pre-
diction algorithm to estimate utilities from a clinical rating scale.
We now report effects of major complications in PD on this pre-
diction algorithm. METHODS: Data from an ongoing prospec-
tive cost study of the German Competence Network of
Parkinson Syndromes was used (n = 115). Our prior utility pre-
diction algorithm was exclusively based on subscales II–IV of 
the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS). Now, 
we applied multivariate regression analysis to investigate 
the independent effect of sociodemographic factors (age, sex), 
neuropsychological disturbances (depression, hallucinations,
dementia) and motor complications (falls, dyskinesia, ﬂuctua-
tions) on utilities measured by the EuroQoL (EQ-5D). Depres-
sion was evaluated by Beck’s Depression Inventory (BDI) and
dementia by Mini Mental State Examination. RESULTS: The
study population had a mean age of 67 years and was predom-
inantly male (67%). Mean EQ-5D was 0.74. Among all com-
plications investigated, only depression reached statistical
signiﬁcance (p = 0.03). UPDRS variables (subscores from part II,
III and IV) remained in the model (see equation): EQ-5D =
(103.23 - 1.29*UPDRS II - 0.30*UPDRS III - 1.23*UPDRS 
IV - 0.55*BDI)/100. After adjusting for UPDRS, depression
reduced the utility by 0.55 score units per BDI point. However,
the inclusion of BDI only marginally improved the explained
variance (adjusted R-square increased from 0.51 to 0.52). CON-
CLUSIONS: Whereas sociodemographic factors, motor compli-
cations and neuropsychological disturbances do not exert
independent effects on utilities when controlling for UPDRS,
depression has an independent effect on EQ-5D. Although
depression is not explicitly included in the UPDRS score of parts
II–IV, its inclusion did not substantially reduce the unexplained
variance. It remains to be investigated which factors further
explain the remaining variance.
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OBJECTIVES: The goal of this cross-sectional analysis was to
determine pain impact on Quality of Life (QoL) and interference
with disability among patients with chronic NeP. METHODS:
Participants in an observational, prospective and multicentre
study in Spain (DONEGA study) with NeP of different etiolo-
gies, completed the Short Form-McGill Pain Questionnaire (SF-
MPQ), the MOS Short Form-12 (SF-12), and the Sheehan
Disability Scale at baseline. RESULTS: A total of 1519 patients
[mean ± SD; 56.0 ± 13.7 years old (58.8% female)] with NeP
were enrolled in the study. Patients had NeP for 1.1 ± 2.8 years,
and 83.3% were on any type of analgesic treatment at baseline:
oral analgesics (51.2%), topical analgesics (26.9%), NSAID’s
(11.1%), antiepileptics (7.3%), and psychoanaleptics (3.5%).
Average Pain scores were 13.1 ± 8.2pts., 10.0 ± 5.8pts., and 3.1
± 3.3pts., for total scale (range 0–45), sensory domain (range
0–33), and affective domain (range 0–12), respectively. Present
pain intensity was 2.8 ± 1.0 (range 0–5) and mean pain past week
on a VAS scale was 71.2 ± 18.9mm. Pain substantially interfered
(≥5 on 0–10 scale) with normal work (6.0 ± 3.1), social life (5.7
± 3.0), and family life (5.3 ± 3.0), then producing disability;
Sheehan total (on 0–30 scale): 17.0 ± 8.4pts. Country normal-
ized physical (PCS) and mental health (MCS) component
summary scores (SF-12) indicated signiﬁcant impairment in both
domains compared to the general Spanish population: PCS; 37.6
± 6.0 vs. 50.1 ± 9.5, and MCS; 45.9 ± 8.1 vs. 50.0 ± 9.6, respec-
tively. Increasing levels of refractory pain, as assessed by number
of medications, corresponded to increasing levels of disability
(Sheehan total: 14.2 ± 8.8 to 16.4 ± 8.3, to 18.7 ± 8.1, and to
20.6 ± 7.0, by 0, 1, 2, and 3 medications respectively, p < 0.01
for all between group comparisons except 2 vs. 3). CONCLU-
SIONS: NeP decreases patients’ physical and mental components
of QoL, while increasing level of disability and impaired normal
work. The disability increases with level of pain treatment 
resistance.
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OBJECTIVES: The goal of this cross-sectional evaluation was to
assess pain impact and interference with mental functioning,
